|December 15, 2017|
|Verastem Announces Pricing of Public Offering of Common Stock|
A shelf registration statement on Form S-3 relating to the public
offering of the shares of common stock described above was declared
effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Certain of the statements made in this press release, including those
relating to Verastem’s public offering, are forward-looking statements.
Each forward-looking statement is subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied in such statement. Applicable risks and
uncertainties include, without limitation: our ability to successfully
complete the offering on terms and conditions satisfactory to us; the
possible adverse impact on the market price of our shares of common
stock due to the dilutive effect of the securities to be sold in the
offering; capital market risks; and the impact of general economic or
industry conditions. There can be no assurance that we will be able to
complete the public offering on the anticipated terms, or at all. You
should not place undue reliance on these forward-looking statements,
which apply only as of the date of this press release. Other risks and
uncertainties include those identified in Verastem’s Annual Report on
Form 10-K for the year ended
|You may automatically receive Verastem Oncology™ financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit. On the next page you will be able to choose from the following options:|
To change your e-mail options at any time, re-enter your e-mail address and click Submit, then adjust your form entries.